CoChat

High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia

Lindström, L., Boberg, K. M., Wikman, O., Friis‐Liby, I., Hultcrantz, R., Prytz, H., Sandberg‐Gertzén, H., Sangfelt, P., Rydning, A., Folvik, G., Gangsøy‐Kristiansen, M., Danielsson, Å., Bergquist, Annika · 2012 · Alimentary Pharmacology & Therapeutics
Cited by 84

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Summary: Background: Patients with primary sclerosing cholangitis ( PSC ) and inflammatory bowel disease ( IBD ) have a high risk of developing colorectal cancer and dysplasia. Ursodeoxycholic acid ( UDCA ) has been suggested to have chemopreventive effects on the development of colorectal cancer and dysplasia but long‐term data and larger trials are lacking. Aim: To evaluate the effect of high dose (17–23 mg/kg/day) UDCA on colorectal neoplasia in a cohort of patients with PSC and IBD . Methods: From our previous 5‐year randomised controlled trial of UDCA vs. placebo in PSC , we performed a follow‐up of 98 patients with concomitant IBD from entry of the trial 1996–1997 until 2009 for development of colorectal cancer or dysplasia. Results: The total follow‐up time was 760 person‐years. Dysplasia/cancer‐free survival was compared between placebo‐ ( n = 50) and UDCA ‐treated ( n = 48) patients. There was a similar frequency of dysplasia or cancer after 5 years between patients originally assigned to UDCA or placebo (13% vs. 16%) and no difference in dysplasia/cancer‐free survival ( P = 0.46, log rank test). At the end of 2009 no difference in cancer‐free survival was detected, 30% of the placebo patients compared with 27% of UDCA patients had developed colorectal cancer or dysplasia. Conclusions: Long‐term high dose ursodeoxycholic acid does not prevent colorectal cancer or dysplasia in patients with primary sclerosing cholangitis ‐associated inflammatory bowel disease .

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2036.2011.04966.x

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 84

Metadata

Authors
Lindström, L., Boberg, K. M., Wikman, O., Friis‐Liby, I., Hultcrantz, R., Prytz, H., Sandberg‐Gertzén, H., Sangfelt, P., Rydning, A., Folvik, G., Gangsøy‐Kristiansen, M., Danielsson, Å., & Bergquist, A.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2012-01-05
Volume
35
Issue
4
Pages
451-457
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W2020569486
Cited by
84
References
4
FWCI
7.64
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia. https://app.cochat.ai/papers/10.1111/j.1365-2036.2011.04966.x
The paper
Lindström, L., Boberg, K. M., Wikman, O., Friis‐Liby, I., Hultcrantz, R., Prytz, H., Sandberg‐Gertzén, H., Sangfelt, P., Rydning, A., Folvik, G., Gangsøy‐Kristiansen, M., Danielsson, Å., & Bergquist, A. (2012). High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.2011.04966.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.